Palvella’s (NASDAQ:PVLA) topical rapamycin gel improved lesions in most patients and showed a favorable safety profile, supporting upcoming FDA discussions on Breakthrough designation and Phase 3 development.
Greenwich LifeSciences (NASDAQ:GLSI) announced an approximately 80% reduction in recurrence rates from a preliminary analysis of the 250-patient open-label arm of its Phase 3 FLAMINGO-01 breast cancer immunotherapy trial, GLSI-100.
Kyverna’s (NASDAQ:KYTX) miv-cel posts robust efficacy and manageable safety in the KYSA-8 trial, paving the way for a planned 2026 BLA filing.
Argenx (ARGX) announced the discontinuation of its Phase 3 UplighTED studies for efgartigimod SC in Thyroid Eye Disease (TED) after an interim analysis by an Independent Data Monitoring Committee (IDMC) indicated futility.
Royal Philips announced an agreement to acquire SpectraWAVE, a Boston-area medical device company, integrating its advanced HyperVue imaging and AI-enabled FFR technology into Philips’ image-guided therapy suite.
Natera (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study.
Acadia Pharmaceuticals (NASDAQ:ACAD) announced today that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a new dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in both adult and pediatric patients aged two years and older.
Relay Therapeutics (NASDAQ:RLAY) presented promising subset efficacy data from its ReDiscover program at the 2025 San Antonio Breast Cancer Symposium (SABCS), showcasing the combination of zovegalisib (RLY-2608) and fulvestrant in a cohort of 52 patients with estrogen receptor-positive breast cancer.
BeyondSpring (NASDAQ:BYSI) presented encouraging results from the Asian subset of its global Phase 3 DUBLIN-3 trial at ESMO Asia 2025, evaluating the combination of plinabulin and docetaxel versus docetaxel alone in second-line and third-line EGFR wild-type non-small cell lung cancer (NSCLC).
OKYO Pharma (NASDAQ:OKYO) announced on December 11, 2025, new analyses from its Phase 2, placebo-controlled, randomized, double-masked trial of 0.05% urcosimod for the treatment of neuropathic corneal pain (NCP).
The trial, involving 18 patients, provided exploratory data on corneal nerve imaging using in vivo confocal microscopy.
